Abstract 137P
Background
Recent single-cell DNA sequencing (scDNA-seq) technologies have enabled the parallel investigation of thousands of individual cells. This is required for accurately reconstructing tumour evolution, during which cancer cells acquire a multitude of different genetic alterations. Although the evolutionary analysis of scDNA-seq datasets is complex due to their unique combination of errors and missing data, several methods have been developed to infer single-cell tumour phylogenies by integrating estimates of the false positive and false negative error rates. This integration relies on the assumption that errors are uniformly distributed both within and across cells. However, this assumption does not always hold; error rates depend on sequencing coverage, which is not constant within or across cells in a sequencing experiment due to, e.g., copy-number alterations and the replication status of a cell, limiting the accuracy of existing methods.
Methods
To address this challenge, we developed PHANTOM, a novel single-cell phylogenetic method that integrates raw sequencing read counts into a statistical framework to robustly correct the errors and missing data. PHANTOM includes bootstrapping to correct for high error frequency genomic positions and a fast probabilistic heuristic based on hypothesis testing to distinguish the remaining errors from truly observed genotypes.
Results
We demonstrate the improved accuracy and robustness of our method compared to existing approaches across several simulation settings. To demonstrate its impact, we applied our method to scDNA-seq datasets comprising >25,000 cells from 31 patients with triple-negative breast cancer or high-grade serous ovarian cancer, as well as targeted scDNA-seq from a cohort of 123 patients with acute myeloid leukaemia, revealing more accurate phylogenies consistent with copy-number alterations.
Conclusions
We developed PHANTOM, a novel single-cell phylogenetic method that accurately and robustly infers single-cell tumour phylogenies. We applied PHANTOM to scDNA-seq cancer datasets, revealing its potential to investigate tumour evolution at unprecedented resolution.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Cancer Research UK.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
25P - Feasibility of digital spatial profiling as a diagnostic: Comparison to immunohistochemistry (IHC)
Presenter: Hannah Hibbs
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Predictive biomarker discovery for ICI treatment response in metastatic MMRd endometrial cancer through deep proteomic profiling of FFPE tissue samples
Presenter: Juan Francisco Grau-Béjar
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Analytical validation of a small amplicon NGS panel for MSI detection
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Clinical significance of TROP2 expression in lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - PTEN/CREBBP/NOTCH1 co-alterations with TP53/RB1 define molecular subtypes associated with primary therapy resistance in small cell lung cancer (SCLC)
Presenter: Louisa Hempel
Session: Cocktail & Poster Display session
Resources:
Abstract
30P - Role of suppressor of cytokine signalling 6 (SOCS6) in colorectal cancer pathogenesis: Integrating clinical and molecular perspectives
Presenter: Asma Al- Bahri
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Adult granulosa cell tumours of ovary: Analysis of 227 non-recurrent and recurrent cases
Presenter: Jan Hojný
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Clinical evaluation cancer testis antigen 45 (CT45) expression in ovarian cancer
Presenter: Harshita Dubey
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Molecular-genetic concordance of the primary tumor and brain metastases of colorectal cancer (GENCONCOR-1)
Presenter: David Halafyan
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - A prognostic signature to predict recurrence in patients with residual disease in triple-negative breast cancer: NACATRINE trial
Presenter: Ana Julia de Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract